{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:46:51Z","timestamp":1793832411225,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00456-6","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:59:05Z","timestamp":1780293545000},"page":"503-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06643442","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn12497973","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-5462","authenticated-orcid":false,"given":"Sebastiano A. G.","family":"Lava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Mallory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chet","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Burch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"9","key":"456_CR1","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1007\/s00431-024-05670-9","volume":"183","author":"BC Henzi","year":"2024","unstructured":"Henzi BC, Lava SAG, Spagnuolo C, et al. Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy. Eur J Pediatr. 2024;183(9):4057\u201362.","journal-title":"Eur J Pediatr"},{"issue":"22","key":"456_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033862","volume":"13","author":"A Breaux","year":"2024","unstructured":"Breaux A, Lang SM, Wittekind S, et al. Cardiac histopathology in Duchenne muscular dystrophy demonstrates diffuse fibrofatty replacement of the myocardium. J Am Heart Assoc. 2024;13(22):e033862.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"456_CR3","volume":"10","author":"JP Bourke","year":"2018","unstructured":"Bourke JP, Bueser T, Quinlivan R. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Cochrane Database Syst Rev. 2018;10(10):CD009068.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"456_CR4","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","volume":"12","author":"M Eagle","year":"2002","unstructured":"Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"456_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103186","volume":"9","author":"R Adorisio","year":"2020","unstructured":"Adorisio R, Mencarelli E, Cantarutti N, et al. Duchenne dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies. J Clin Med. 2020;9(10):3186.","journal-title":"J Clin Med"},{"issue":"2","key":"456_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-001977","volume":"9","author":"J Bourke","year":"2022","unstructured":"Bourke J, Turner C, Bradlow W, et al. Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart. 2022;9(2):e001977.","journal-title":"Open Heart"},{"issue":"6","key":"456_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cardfail.2012.03.001","volume":"18","author":"JW Rossano","year":"2012","unstructured":"Rossano JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail. 2012;18(6):459\u201370.","journal-title":"J Card Fail"},{"key":"456_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133521","volume":"438","author":"SAG Lava","year":"2025","unstructured":"Lava SAG. SGLT2 inhibitors for paediatric heart failure: time for innovative trials. Int J Cardiol. 2025;438:133521.","journal-title":"Int J Cardiol"},{"issue":"2","key":"456_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ehf2.12082","volume":"3","author":"RE Andrews","year":"2016","unstructured":"Andrews RE, Fenton MJ, Dominguez T, Burch M, British Congenital Cardiac Association. Heart failure from heart muscle disease in childhood: a 5-10\u00a0year follow-up study in the UK and Ireland. ESC Heart Fail. 2016;3(2):107\u201314.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"456_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","volume":"44","author":"DM Newland","year":"2023","unstructured":"Newland DM, Law YM, Albers EL, et al. Early clinical experience with dapagliflozin in children with heart failure. Pediatr Cardiol. 2023;44(1):146\u201352.","journal-title":"Pediatr Cardiol"},{"issue":"6","key":"456_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ahj.2008.01.018","volume":"155","author":"DM Connuck","year":"2008","unstructured":"Connuck DM, Sleeper LA, Colan SD, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008;155(6):998\u20131005.","journal-title":"Am Heart J"},{"issue":"15","key":"456_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"21","key":"456_CR13","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386(21):2024\u201334.","journal-title":"N Engl J Med"},{"key":"456_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100933","volume":"36","author":"R Cardoso","year":"2021","unstructured":"Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100933.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"456_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4\u2013131.","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"456_CR16","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263\u2013421.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"456_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"456_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/psp4.12426","volume":"8","author":"G Helmlinger","year":"2019","unstructured":"Helmlinger G, Sokolov V, Peskov K, et al. Quantitative systems pharmacology: an exemplar model-building workflow with applications in cardiovascular, metabolic, and oncology drug development. CPT Pharmacometr Syst Pharmacol. 2019;8(6):380\u201395.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"456_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40272-024-00623-z","volume":"26","author":"SA Lava","year":"2024","unstructured":"Lava SA, Laurence C, Di Deo A, Sekarski N, Burch M, Della Pasqua O. Dapagliflozin and empagliflozin in paediatric indications: a systematic review. Pediatr Drugs. 2024;26(3):229\u201343.","journal-title":"Pediatr Drugs"},{"issue":"19","key":"456_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021037","volume":"10","author":"SE Henson","year":"2021","unstructured":"Henson SE, Lang SM, Khoury PR, et al. The effect of adiposity on cardiovascular function and myocardial fibrosis in patients with Duchenne muscular dystrophy. J Am Heart Assoc. 2021;10(19):e021037.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"456_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.21037\/qims-23-790","volume":"14","author":"W Yuan","year":"2024","unstructured":"Yuan W, Xu H, Yu L, et al. Association of increased epicardial adipose tissue derived from cardiac magnetic resonance imaging with myocardial fibrosis in Duchenne muscular dystrophy: a clinical prediction model development and validation study in 283 participants. Quant Imaging Med Surg. 2024;14(1):736\u201348.","journal-title":"Quant Imaging Med Surg"},{"issue":"16","key":"456_CR22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"1","key":"456_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCIMAGING.110.960740","volume":"4","author":"D Verhaert","year":"2011","unstructured":"Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging. 2011;4(1):67\u201376.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"456_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ajpath.2025.11.002","volume":"196","author":"C Dostal","year":"2026","unstructured":"Dostal C, Reiner J, Antunes Goncalves AI, et al. Targeting skeletal muscle in Duchenne muscular dystrophy: integrating in silico and experimental approaches to sodium-glucose cotransporter-2 inhibition. Am J Pathol. 2026;196(3):745\u201365.","journal-title":"Am J Pathol"},{"issue":"2","key":"456_CR25","doi-asserted-by":"publisher","first-page":"H418","DOI":"10.1152\/ajpheart.00729.2023","volume":"326","author":"J Sauer","year":"2024","unstructured":"Sauer J, Marksteiner J, Lilliu E, et al. Empagliflozin treatment rescues abnormally reduced Na+ currents in ventricular cardiomyocytes from dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol. 2024;326(2):H418\u201325.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"456_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","volume":"70","author":"M Cella","year":"2010","unstructured":"Cella M, Knibbe C, Danhof M, Della Pasqua O. What is the right dose for children? Br J Clin Pharmacol. 2010;70:597\u2013603.","journal-title":"Br J Clin Pharmacol"},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/HYPERTENSIONAHA.107.108886","volume":"51","author":"DK Benjamin Jr","year":"2008","unstructured":"Benjamin DK Jr, Smith PB, Jadhav P, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51:834\u201340.","journal-title":"Hypertension"},{"issue":"9","key":"456_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/jcph.708","volume":"56","author":"F Bellanti","year":"2016","unstructured":"Bellanti F, Di Iorio VL, Danhof M, Della Pasqua O. Sampling optimization in pharmacokinetic bridging studies: example of the use of deferiprone in children with \u03b2-thalassemia. J Clin Pharmacol. 2016;56(9):1094\u2013103.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"456_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/pharmaceutics16070872","volume":"16","author":"R Simeoli","year":"2024","unstructured":"Simeoli R, Lava SAG, Di Deo A, et al. Pharmacokinetic evaluation of oral viscous budesonide in paediatric patients with eosinophilic oesophagitis in repaired oesophageal atresia. Pharmaceutics. 2024;16(7):872.","journal-title":"Pharmaceutics"},{"key":"456_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1522131","volume":"12","author":"SAG Lava","year":"2026","unstructured":"Lava SAG, Di Deo A, D\u2019Agate S, Della Pasqua O. Empagliflozin in paediatric heart failure: model-based optimisation of a pharmacokinetic bridging study. Front Med (Lausanne). 2026;12:1522131.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"456_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1163\/157180908X333228","volume":"15","author":"European Union","year":"2008","unstructured":"European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Eur J Health Law. 2008;15(2):223\u201350.","journal-title":"Eur J Health Law"},{"key":"456_CR32","unstructured":"European Medicines Agency. ICH Topic E 11 Clinical Investigation of Medicinal Products in the Paediatric Population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP\/ICH\/2711\/99). January 2021. https:\/\/www.ema.europa.eu\/en\/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-scientific-guideline. Accessed Nov 18, 2025."},{"issue":"1","key":"456_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ijpharm.2013.08.068","volume":"457","author":"SA Lava","year":"2013","unstructured":"Lava SA, Simonetti GD, Bianchetti AA, Ferrarini A, Bianchetti MG. Prevention of vitamin\u00a0D insufficiency in Switzerland: a never-ending story. Int J Pharm. 2013;457(1):353\u20136.","journal-title":"Int J Pharm"},{"issue":"4","key":"456_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001338","volume":"4","author":"A Tandon","year":"2015","unstructured":"Tandon A, Villa CR, Hor KN, et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. J Am Heart Assoc. 2015;4(4):e001338.","journal-title":"J Am Heart Assoc"},{"key":"456_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00467-014-2931-3","volume":"30","author":"SA Lava","year":"2015","unstructured":"Lava SA, Bianchetti MG, Simonetti GD. Salt intake in children and its consequences on blood pressure. Pediatr Nephrol. 2015;30:1389\u201396.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"456_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.120.011526","volume":"13","author":"S Siddiqui","year":"2020","unstructured":"Siddiqui S, Alsaied T, Henson SE, et al. Left ventricular magnetic resonance imaging strain predicts the onset of Duchenne muscular dystrophy-associated cardiomyopathy. Circ Cardiovasc Imaging. 2020;13(11):e011526.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"456_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/jcph.1051","volume":"58","author":"J Mondick","year":"2018","unstructured":"Mondick J, Riggs M, Kaspers S, Soleymanlou N, Marquard J, Nock V. Population pharmacokinetic-pharmacodynamic analysis to characterize the effect of empagliflozin on renal glucose threshold in patients with type\u00a01 diabetes mellitus. J Clin Pharmacol. 2018;58(5):640\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"456_CR38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0223","volume":"138","author":"N Pica","year":"2016","unstructured":"Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics. 2016;138(3):e20160223.","journal-title":"Pediatrics"},{"issue":"5","key":"456_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00431-018-3110-5","volume":"177","author":"SA Lava","year":"2018","unstructured":"Lava SA, Elie V, Ha PTV, Jacqz-Aigrain E. Sequential analysis in neonatal research-systematic review. Eur J Pediatr. 2018;177(5):733\u201340.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"456_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00246-023-03332-5","volume":"46","author":"A Konduri","year":"2025","unstructured":"Konduri A, West C, Lowery R, et al. Experience with SGLT2 inhibitors in patients with single ventricle congenital heart disease and fontan circulatory failure. Pediatr Cardiol. 2025;46(1):81\u20138.","journal-title":"Pediatr Cardiol"},{"issue":"435","key":"456_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133384","volume":"15","author":"SS Kumar","year":"2025","unstructured":"Kumar SS, Gopalakrishnan A, Krishnamoorthy KM, Naik S, Sivadasanpillai H. The efficacy and safety of dapagliflozin in pediatric heart failure. Int J Cardiol. 2025;15(435):133384.","journal-title":"Int J Cardiol"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00456-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00456-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00456-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:23:45Z","timestamp":1788405825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00456-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00456-6","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chet Villa has received consulting fees from Sarepta, Capricor, Edgewise, MLBio, and Regenx. However, none of these pertain to the topic of this current manuscript. Sebastiano A.G. Lava is an Editorial Board member of\n                      Cardiology and Therapy\n                      . Sebastiano A.G. Lava was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Craig Laurence, Janet Mallory, Oscar Della Pasqua, Alessandro Di Deo, Sean Lang, Michael Quail, and Michael Burch have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has received ethical approval and is registered under International Standard Randomised Controlled Trial Number ISRCTN 12497973, as well as at ClinicalTrials.gov (NCT06643442). The REDMeD Trial will be conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. The study protocol for the REDMeD trial was reviewed and approved by the London\u2014Hampstead Research Ethics Committee (25\/LO\/0361) and by the UK Medicines and Healthcare products Regulatory Agency, MHRA (IRAS number 1009946). Survey participants consented to the anonymized use of their information.\u00a0Written consent was obtained by parents, oral assent by children, according to their age and development.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}